Generic placeholder image

Current Pharmaceutical Biotechnology


ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

The Ins and Outs of RNAi in Mammalian Cells

Author(s): M. Banan and N. Puri

Volume 5, Issue 5, 2004

Page: [441 - 450] Pages: 10

DOI: 10.2174/1389201043376643

Price: $65


The ability to utilize the RNA interference (RNAi) machinery for silencing target-gene expression has created a lot of excitement in the research community. RNAi in mammalian cells is achieved through introduction or expression of 21-23 bp small interfering RNAs (siRNAs) in cells or animals. Currently, there are six ways of producing siRNAs. siRNAs can be produced by chemical synthesis, in vitro transcription, or RNase III/Dicer digestion of long dsRNAs. Alternatively, they can be expressed in vivo from plasmids, PCR cassettes, or viral vectors that include a CMV or polymerase III (pol III) transcription unit. So far, these approaches have been used to create siRNAs for use in loss-offunction studies. However, it is clear that siRNAs also hold great promise as therapeutic tools. First, their activity seems to be very sequence-specific. Moreover, siRNAs could be modified in order to increase their stability and potency in vivo. Here, we will review the issues and findings related to siRNA design and production. Moreover, we will summarize new findings on siRNA specificity, modification, and delivery, which are critical to their use as therapeutic agents.

Keywords: rna interference, double-stranded rna, small interfering rna, small hairpin rna, rna-induced silencing, complex, viral vectors, gene knockdown

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy